Drug intelligence / Profile preview

Locafen

Development stage: Unknown
Lead developer: Apeks Pharma
Modality: Small Molecules
Administration: Topical, Rectal

Overview

Locafen is a topical cream formulation containing 2% diltiazem hydrochloride, a calcium channel blocker. It is marketed by Apeks Pharma in Turkey and manufactured by İlko İlaç. The drug is specifically indicated for the treatment of chronic anal fissures and associated anorectal conditions. By blocking L-type calcium channels in the vascular smooth muscle of the internal anal sphincter, diltiazem promotes muscle relaxation, reduces resting anal pressure, and improves local blood flow, which facilitates the healing of the fissure. It represents a non-surgical pharmacological alternative for patients with chronic anorectal symptoms.

Brand names: Locafen
Other names: diltiazem hydrochloride 2% cream

Targets

LTCC (Voltage-gated calcium channel (L-type))

Beyond the preview

Go deeper on Locafen.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Locafen.

Explore the full profile